In:
International Journal of Clinical Trials, Medip Academy, Vol. 3, No. 4 ( 2016-10-22), p. 217-
Abstract:
〈 p class="abstract" 〉 〈 strong 〉 Background: 〈 /strong 〉 〈 span lang="EN-IN" 〉 Abdominal aortic aneurysms (AAAs) are a leading cause of mortality worldwide but have no recognised medical therapy. Pre-clinical studies indicate that osteopontin plays an important role in the pathogenesis of AAA via a number of mechanisms. This trial aims to assess the potential of fenofibrate to favourably alter biomarkers associated with AAA pathology. 〈 /span 〉 〈 /p 〉 〈 p class="abstract" 〉 〈 strong 〉 Methods: 〈 /strong 〉 〈 span lang="EN-IN" 〉 Fenofibrate in the management of AbdoMinal aortic anEurysm (FAME)-2 is a multi-centre, prospective, randomised, double-blind, placebo-controlled clinical trial to assess the effect of 24 weeks of oral therapy with 145 mg of fenofibrate on key pathological markers of AAA. A total of 140 participants with an AAA measuring between 35-49 mm will be randomly assigned to either 145 mg of fenofibrate once per day or identical placebo for a period of 24 weeks. Primary outcome measures will be serum concentrations of osteopontin and kallistatin. Secondary outcome measures will include serum levels of resistin, lipids, matrix metalloproteinases and pro-inflammatory cytokines, circulating concentrations of AAA biomarkers, and AAA diameter as assessed by ultrasound. 〈 /span 〉 〈 /p 〉 〈 p class="abstract" 〉 〈 strong 〉 Conclusions: 〈 /strong 〉 This study represents the next step in the assessment of a potential novel medical therapy for AAA. 〈 /p 〉
Type of Medium:
Online Resource
ISSN:
2349-3259
,
2349-3240
DOI:
10.18203/2349-3259.ijct20163960
Language:
Unknown
Publisher:
Medip Academy
Publication Date:
2016
Permalink